Want to see HK:9877 full AI Analyst Report?
Top Page
Jenscare Scientific Co. Ltd. Class H
(9877)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$7.50
▼(-20.89% Downside)
Action:Reiterated
Date:06/27/26
The score is held down primarily by weak profitability and continued cash burn despite strong revenue growth and high gross margins. Technicals add pressure as the stock trades below all key moving averages with bearish MACD, although oversold readings provide some near-term stabilization potential. Valuation remains difficult to support given negative earnings and no indicated dividend yield.
Positive Factors
Revenue ramp / commercialization
A rapid revenue ramp to ~88.2M demonstrates the company has moved from development to commercial sales, indicating product adoption and distribution progress. This structural commercialization reduces execution risk and lays groundwork for operating leverage as volumes grow over months.
Negative Factors
Large net losses
A net loss of ~264.2M far exceeds current revenue, showing operating expenses and investment run-rate materially outpace sales. Persistently large losses are a structural constraint on shareholder value, likely necessitating material cost control or external financing to reach sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue ramp / commercialization
A rapid revenue ramp to ~88.2M demonstrates the company has moved from development to commercial sales, indicating product adoption and distribution progress. This structural commercialization reduces execution risk and lays groundwork for operating leverage as volumes grow over months.
Read all positive factors
Jenscare Scientific Co. Ltd. Class H (9877) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.26B
Dividend YieldN/A
Average Volume (3M)805.10K
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue GrowthN/A
EPS Growth-56.25%
CountryHK
Employees195
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-0.44
Shares Outstanding310,306,200
10 Day Avg. Volume637,060
30 Day Avg. Volume805,099
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.22
Price to Sales (P/S)37.79
P/FCF Ratio-41.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)HK$261.02M
Jenscare Scientific Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Jenscare Scientific Co., Ltd. operates as a medical technology enterprise dedicated to advancing interventional therapies for structural heart conditions within the People's Republic of China. Among its pipeline, the company features LuX-Valve, an...
How the Company Makes Money
null...
Jenscare Scientific Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 88.24M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 66.60M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -210.22M | -202.04K | -429.68M | -504.82M | -501.77M |
| Net Income | -264.21M | -177.51K | -371.74M | -439.31M | -500.52M |
Balance Sheet | |||||
| Total Assets | 896.62M | 1.03B | 1.33B | 1.43B | 1.34B |
| Cash, Cash Equivalents and Short-Term Investments | 527.63M | 605.99M | 1.09B | 825.11M | 800.59M |
| Total Debt | 47.38M | 64.42M | 44.08M | 3.87M | 2.41M |
| Total Liabilities | 123.16M | 110.61M | 100.84M | 58.30M | 50.77M |
| Stockholders Equity | 789.75M | 931.76M | 1.23B | 1.37B | 1.29B |
Cash Flow | |||||
| Free Cash Flow | -80.08M | -288.81M | -300.64M | -208.03M | -157.25M |
| Operating Cash Flow | -75.00M | -217.55M | -222.44M | -158.48M | -141.89M |
| Investing Cash Flow | 5.96M | 5.59M | 358.13M | -146.58M | -475.07M |
| Financing Cash Flow | -20.61M | -110.74M | 56.44M | 188.93M | 1.08B |
Jenscare Scientific Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Neutral | HK$6.72B | 16.82 | 12.01% | 1.26% | 10.19% | 23.70% | |
69 Neutral | HK$6.99B | 23.53 | 11.30% | ― | 25.24% | 7.29% | |
61 Neutral | HK$6.31B | 36.98 | 4.06% | ― | 5.10% | -32.48% | |
59 Neutral | HK$2.97B | 56.62 | 2.07% | ― | 91.69% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$4.26B | -14.85 | -22.25% | ― | ― | -56.25% | |
44 Neutral | HK$3.00B | -11.66 | -11.27% | ― | 16.35% | 9.84% |
* Healthcare Sector Average
HK:9877
Jenscare Scientific Co. Ltd. Class H
7.55
-0.69
-8.37%
HK:9996
Peijia Medical Ltd.
4.04
-4.11
-50.43%
HK:1302
LifeTech Scientific Corporation
1.41
-0.38
-21.23%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
32.90
10.68
48.04%
HK:1789
AK Medical Holdings Ltd.
5.83
0.05
0.93%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.02
0.61
9.52%
Jenscare Scientific Co. Ltd. Class H Corporate Events
Jenscare Marks Key Milestone in Global Trial for LuX-Valve Plus
Jul 16, 2026
Jenscare Scientific announced that its proprietary LuX-Valve Plus transvenous tricuspid valve replacement system has successfully completed implantation in the first batch of enrolled subjects in an FDA-approved pivotal registration trial. The dev...
Jenscare Wins EU MDR CE Mark for LuX-Valve Plus, Advancing Global Heart-Device Push
Jul 8, 2026
Jenscare Scientific Co., Ltd. announced that its proprietary transvenous tricuspid valve replacement system, LuX-Valve Plus, has obtained CE certification under the EU Medical Device Regulation, marking a key step in the group’s internationa...
Jenscare Wins Hong Kong Approval for Ken-Valve Heart Valve System
Jun 21, 2026
Jenscare Scientific Co., Ltd. has received approval from Hong Kong’s Department of Health for its Ken-Valve Transcatheter Aortic Valve Replacement System, a device designed to treat aortic regurgitation and combined aortic stenosis. The comp...
Jenscare Scientific Reports Poll Results and High Turnout at 2025 AGM
May 28, 2026
Jenscare Scientific Co., Ltd. held its 2025 annual general meeting in Ningbo, Zhejiang, with the board convening the session in compliance with PRC company law, Hong Kong listing rules, and the firm’s articles of association. All directors a...
Jenscare’s LuX-Valve Plus Shows Strong One-Year Results in Large Annulus Tricuspid Patients
May 20, 2026
Jenscare Scientific reported new twelve-month follow-up data from the EU TRINITY study of its LuX-Valve Plus transcatheter tricuspid valve replacement in large annulus patients, presented at EuroPCR 2026. The global, multi-center trial enrolled 16...
Jenscare Scientific Calls 2025 AGM and Seeks Mandate for New Financing
Apr 28, 2026
Jenscare Scientific Co., Ltd. has convened its 2025 annual general meeting for 28 May 2026 in Ningbo, Zhejiang, where shareholders will review the board report, audited consolidated financial statements, annual report, and profit distribution plan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.